Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-20 (IGHV3-20) is a gene segment coding for the variable region of the heavy chain of immunoglobulins (antibodies)[1][5]. IGHV3-20 encodes the V (variable) domain of the antibody heavy chain, which is essential for forming the antigen-binding site together with the light chain variable region[1][3]. This variable region enables antigen recognition and binding, which is the fundamental activity of antibodies in humoral immunity. The specific sequence variability of IGHV3-20, shaped by V-(D)-J rearrangement and somatic hypermutation, contributes to the diversity and affinity maturation of antibodies produced by B lymphocytes[1][2][3]. IGHV3-20, like other IGHV genes, participates in immune defense by allowing plasma cells and B cells to generate highly variable and specific antibodies to a wide range of antigens[1][2]. IGHV gene polymorphisms, including those at IGHV3-20, can affect the breadth, potency, and specificity of immune responses in health and disease and are implicated in the context of infectious diseases, cancers (such as B-cell lymphomas), and other immune-related conditions[7][2]. However, IGHV3-20 itself is a germline gene segment and not a stand-alone protein, receptor, or drug target; its medical importance is indirect, relating to its contribution to antibody specificity and diversity rather than being a direct therapeutic target[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 3-20 (IGHV3-20).